Hepatotoxicity associated with nevirapine use

被引:84
作者
Baylor, MS [1 ]
Johann-Liang, R [1 ]
机构
[1] US FDA, Div Antiviral Drug Prod, Rockville, MD 20857 USA
关键词
D O I
10.1097/00126334-200404150-00014
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
引用
收藏
页码:538 / 539
页数:2
相关论文
共 9 条
[1]  
BARLETT J, SEVERE LIVER TOXICIT
[2]  
BAYLOR M, 2003, MED OFF REV
[3]  
*BOEHR ING PHARM I, VIR PACK INS
[4]  
BOXWELL D, 2001, MMWR-MORBID MORTAL W, V49, P1153
[5]  
HAVERKOS H, 2002, MED OFFICERS REV
[6]  
IMPERIALE SM, 2002, 4 INT WORKSH ADV EV
[7]  
LYONS F, 2003, INT AIDS SOC JUL 13
[8]  
STERN J, 2002, 14 INT AIDS C JUL 7
[9]   A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients [J].
Stern, JO ;
Robinson, PA ;
Love, J ;
Lanes, S ;
Imperiale, MS ;
Mayers, DL .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 34 :S21-S33